

IN RE APPLICATION: Ram PRATAP, et al.

GROUP ART UNIT: 1615

SERIAL NUMBER: 09/742,424

EXAMINER: Todd Ware

FILED: December 22, 2000

FOR: NOVEL USES OF GUGULIPID: AS COGNITION ENHANCER, ANTI-HYPERGLYCEMIC AND FOR DERMATOLOGICAL CONDITIONS



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

BEST AVAILABLE COPY

Sir:

Applicant(s) wish(es) to disclose the following information.

BEST AVAILABLE COPY

REFERENCES

- Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. Copies of the listed documents are attached, where required, as are either statements of relevancy or any readily available full or partial English translations of any non-English-language documents. Please note, that both references were previously identified on a Form PTO-1449 and the Flood, et al. reference was previously submitted with the Information Disclosure Statement filed on April 29, 2002. However, since it was not initialed as being considered by the Examiner on the PTO-1449 copy returned with the Office Action dated May 7, 2002 (Paper No. 7), it is being resubmitted as courtesy.

RELATED CASES

- Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

- without fee and within three months of the filing date of the application.
- without fee and within three months of the date of entry of the U.S. national stage.
- without fee since the references were made of record on the Form PTO-1449 filed on April 29, 2002.
- without fee and with the appropriate certification above.
- without fee and with a new CPA application.
- without fee and with a Request for Continued Examination.
- with fee and before the mailing date of any of a Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

Respectfully submitted,

PIPER RUDNICK LLP

Wilburn L. Chesser
Attorney of Record
Registration No. 41,668

Patrick R. Delaney
Registration No. 45,338

1200 Nineteenth Street, N.W.
Washington, DC 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Susan
202 861
0678



PIPER RUDNICK LLP
1200 NINETEENTH STREET, NW
WASHINGTON, DC 20036-2412
TELEPHONE: 202-861-3900
FACSIMILE: 202-223-2085

1615
RECEIVED
FEB - 5 2003
TECH. CENTER 1600/2000

DOCKET NO.: K&S-0100-US

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Re: Serial No.: 09/742,424
Applicant(s): Ram PRATAP, et al.
Filing Date: December 22, 2000
For: NOVEL USES OF GUGULIPID: AS COGNITION ENHANCER, ANTI-HYPERGLYCEMIC AND FOR DERMAL CONDITIONS
Group Art Unit: 1615
Examiner: Todd Ware

SIR:

Attached hereto for filing are the following papers:

FEE TRANSMITTAL
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
FORM PTO-1449
CITED DOCUMENTS (2)

Our check in the amount of \$ -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary extension of time to make the filing of the attached documents timely, please charge or credit the difference to Deposit Account No. 50-1442. Further, if these papers are not considered timely filed, then a request is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

PIPER RUDNICK LLP

Wilburn L. Chesser
Attorney of Record
Registration No.: 41,668

Patrick R. Delaney
Registration No.: 45,338